The DOI matches its Crossref record; 96 of the 100 references it cites were found in a registry or an index.
Glucagon-like peptide analogues for type 2 diabetes mellitus
Open accessAbstract
BACKGROUND: Glucagon-like peptide analogues are a new class of drugs used in the treatment of type 2 diabetes that mimic the endogenous hormone glucagon-like peptide 1 (GLP-1). GLP-1 is an incretin, a gastrointestinal hormone that is released into the circulation in response to ingested nutrients. GLP-1 regulates glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis, and by suppressing glucagon secretion, delayed gastric emptying and promoting satiety. OBJECTIVES: To assess the effects of glucagon-like peptide analogues in patients with type 2 diabetes mellitus. SEARCH STRATEGY: Studies were obtained from electronic searches of The Cochrane Library (last search issue 1, 2011), MEDLINE (last search March 2011), EMBASE (last search March 2011), Web of Science (last search March 2011) and databases of ongoing trials. SELECTION CRITERIA: Studies were included if they were randomised controlled trials of a minimum duration of eight weeks comparing a GLP-1 analogue with placebo, insulin, an oral anti-diabetic agent, or another GLP-1 analogue in people with type 2 diabetes. DATA COLLECTION AND ANALYSIS: Data extraction and quality assessment of studies were done by one reviewer and checked by a second. Data were analysed by type of GLP-1 agonist and comparison treatment. Where appropriate, data were summarised in a meta-analysis (mean differences and risk ratios summarised using a random-effects model). MAIN RESULTS: Seventeen randomised controlled trials including relevant analyses for 6899 participants were included in the analysis. Studies were mostly of short duration, usually 26 weeks.In comparison with placebo, all GLP-1 agonists reduced glycosylated haemoglobin A1c (HbA1c) levels by about 1%. Exenatide 2 mg once weekly and liraglutide 1.8 mg reduced it by 0.20% and 0.24% respectively more than insulin glargine. Exenatide 2 mg once weekly reduced HbA1c more than exenatide 10 μg twice daily, sitagliptin and pioglitazone. Liraglutide 1.8 mg reduced HbA1c by 0.33% more than exenatide 10 μg twice daily. Liraglutide led to similar improvements in HbA1c compared to sulphonylureas but reduced it more than sitagliptin and rosiglitazone.Both exenatide and liraglutide led to greater weight loss than most active comparators, including in participants not experiencing nausea. Hypoglycaemia occurred more frequently in participants taking concomitant sulphonylurea. GLP-1 agonists caused gastrointestinal adverse effects, mainly nausea. These adverse events were strongest at the beginning and then subsided. Beta-cell function was improved with GLP-1 agonists but the effect did not persist after cessation of treatment.None of the studies was long enough to assess long-term positive or negative effects. AUTHORS' CONCLUSIONS: GLP-1 agonists are effective in improving glycaemic control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
A Coefficient of Agreement for Nominal Scales
Cohen, J. (1960) · Educational and Psychological Measurement · doi:10.1177/001316446002000104 · Cited by 42,398
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,325
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Flagged first, then by citations
4 of the 100 references couldn’t be matched to a known paper.
Research works printed but not linked: 8
- Best, 2008, Higher diabetes treatment satisfaction associated with improved glucose control for both exenatide once weekly and twice daily, Diabetes, 57, A520
- Trautmann, 2007, Less hypoglycemia with exenatide versus insulin glargine, despite similar Hba(1c) improvement, in patients with T2dm adjunctively treated with metformin, Diabetes, 56, A45
- Trautmann, 2007, Relationship between hypoglycaemia, background oral antidiabetic agent, and glycaemic control in patients treated with exenatide or insulin glargine, Diabetologia, 50, S338
- Trescoli-Serrano, 2005, Clinical site experience comparing insulin glargine with exenatide treatment in type 2 diabetic patients, Diabetologia, 48, A3
- Valentine, 2007, Projecting the long-term clinical benefits of treatment with the GLP-1 analogue liraglutide in subjects with type 2 diabetes, Diabetes, 56, A568
- Journal Watch FDA Reminds Clinicians of Liraglutide's Risks for Pancreatitis and Cancer http://firstwatch.jwatch.org/cgi/content/full/2011/614/2?q=topic_diabetes
- Kaku, 2010, Improved glycaemic control with minimal hypoglycaemiaand no weight change with the once-daily humanglucagon-like peptide-1 analogue liraglutide as add-onto sulphonylurea in Japanese patients with type 2 diabetes, Diabetes, Obesity and Metabolism, 12, 341–7, 10.1111/j.1463-1326.2009.01194.x · DOI
- Loh, 2007, Efficacy of exenatide therapy over 12 months in a "real world" setting, Diabetes, 56, A152
Cited by
Sorted by citations
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Gilbert, M. P., & Pratley, R. E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00178 · Cited by 407
Zheng, S. L., Roddick, A., Agha-Jaffar, R., Shun-Shin, M. J., Francis, D. P., Oliver, N. S., & Meeran, K. M. (2018) · JAMA · doi:10.1001/jama.2018.3024 · Cited by 409
Nathan, D. M. (2015) · JAMA · doi:10.1001/jama.2015.9536 · Cited by 398
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., & Lerch, C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006739.pub2 · Cited by 308
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Khunti, K., Alsifri, S., Aronson, R., Cigrovski Berković, M., Enters‐Weijnen, C., Forsén, T., Galstyan, G., Geelhoed‐Duijvestijn, P., Goldfracht, M., Gydesen, H., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12689 · Cited by 276
Targeting GLP-1 receptor trafficking to improve agonist efficacy
Jones, B. J., Buenaventura, T., Kanda, N., CHABOSSEAU, P. L., Owen, B. M., Scott, R., Goldin, R. D., Angkathunyakul, N., Junior, I. R. C., Bosco, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03941-2 · Cited by 274
Current treatments for obesity
Ruban, A., Stoenchev, K. V., Ashrafian, H., & TEARE, J. P. (2019) · Clinical Medicine · doi:10.7861/clinmedicine.19-3-205 · Cited by 297
A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets
Marchetti, P., Lupi, R., Bugliani, M., Kirkpatrick, C. L., Sebastiani, G., Grieco, F. A., Guerra, S. D., D’Aleo, V., Piro, S., Marselli, L., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2716-9 · Cited by 267
Altered gut and adipose tissue hormones in overweight and obese individuals: Cause or consequence?
Lean, M. E. J., & Malkova, D. (2016) · International Journal of Obesity · doi:10.1038/ijo.2015.220 · Cited by 253
Bharucha, A. E., Kudva, Y. C., & Prichard, D. O. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00161 · Cited by 252
Body Weight Considerations in the Management of Type 2 Diabetes
Apovian, C. M., Okemah, J., & O'Neil, P. M. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0824-8 · Cited by 253
Coronary heart disease risk: Low-density lipoprotein and beyond
Shaya, G. E., Leucker, T. M., Jones, S. R., Martin, S. S., & Toth, P. P. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.04.002 · Cited by 247
Edridge, C. L., Dunkley, A. J., Bodicoat, D. H., Rose, T. C., Gray, L. J., Davies, M. J., & Khunti, K. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126427 · Cited by 230
Wang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., Ni, Y., Liu, D., & Zhu, Z. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12085 · Cited by 225
Firouzi, S., Majid, H. A., Ismail, A., Kamaruddin, N. A., & Yusof, B. N. M. (2016) · European Journal of Nutrition · doi:10.1007/s00394-016-1199-8 · Cited by 227
van Baar, M. J. B., van Ruiten, C. C., Muskiet, M. H. A., van Bloemendaal, L., IJzerman, R. G., & van Raalte, D. H. (2018) · Diabetes Care · doi:10.2337/dc18-0588 · Cited by 208
The regulation of food intake by the gut-brain axis: implications for obesity
Hussain, S., & Bloom, S. R. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.93 · Cited by 204
Probiotics: How Effective Are They in the Fight against Obesity?
Mazloom, K., Siddiqi, I., & Covașă, M. (2019) · Nutrients · doi:10.3390/nu11020258 · Cited by 210
Powell, D. R., Smith, M. G., Greer, J., Harris, A. L., Zhao, S., DaCosta, C. M., Mseeh, F., Shadoan, M. K., Sands, A., Zambrowicz, B., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203364 · Cited by 189
Should metformin remain the first-line therapy for treatment of type 2 diabetes?
Baker, C., Retzik-Stahr, C., Singh, V., Plomondon, R., Anderson, V., & Rasouli, N. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820980225 · Cited by 204
Glucose variability: An emerging target for the treatment of diabetes mellitus
Frontoni, S., Bartolo, P. D., Avogaro, A., Bosi, E., Paolisso, G., & Ceriello, A. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.09.007 · Cited by 176
Muller, D. R. P., Stenvers, D. J., Malekzadeh, A., Holleman, F., Painter, R. C., & Siegelaar, S. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1215356 · Cited by 174
Sun, F., Chai, S., Yu, K., Quan, X., Yang, Z., Wu, S., Zhang, Y., Ji, L., Wang, J., & Shi, L. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0188 · Cited by 158
Improved glycemic control in mice lacking Sglt1 and Sglt2
Powell, D. R., DaCosta, C. M., Gay, J. P., Ding, Z., Smith, M. G., Greer, J., Doree, D. D., Jeter-Jones, S. L., Mseeh, F., Rodriguez, L. A., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00439.2012 · Cited by 161
Guideline Development Group., Bilo, H. J. G., Coentrão, L., Couchoud, C., Covic, A. C., SUTTER, J. D., Drechsler, C., Gnudi, L., Goldsmith, D. J. A., Heaf, J. G., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv100 · Cited by 155
A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson’s Disease
Tabrez, S. S. M., Jabir, N. R., Shakil, S., Greig, N. H., Alam, Q., Abuzenadah, A. M., Damanhouri, G., & Kamal, M. A. (2012) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152712800792785 · Cited by 153
Long-term effects of weight-reducing drugs in people with hypertension
Siebenhofer, A., Jeitler, K., Horvath, K., Berghold, A., Posch, N. A. S., Meschik, J., & Semlitsch, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub4 · Cited by 118
The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
Thomas, M. C. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30069-1 · Cited by 107
Rosiglitazone for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., Clar, C., & Ebrahim, S. H. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006063.pub2 · Cited by 106
Self-citationControl of insulin secretion by GLP-1
Jones, B. J., Bloom, S. R., Buenaventura, T., Tomás, A., & Rutter, G. A. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.013 · Cited by 99
Tratamiento de la diabetes tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Díez‐Espino, J., Formiga, F., Tejedor, J. L., Rodríguez‐Mañas, L., González-Sarmiento, E., Torre, E. L. M., & Sangrós, J. (2012) · Medicina Clínica · doi:10.1016/j.medcli.2012.10.003 · Cited by 96
Darsalia, V., Hua, S., Larsson, M., Mallard, C., Nathanson, D., Nyström, T., Sjöholm, Å., Johansson, M. E., & Patrone, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103114 · Cited by 92
Wong, C., Lee, M. H., Yaow, C. Y. L., Chin, Y. H., Goh, X. L., Ng, C. H., Lim, A. Y. L., Muthiah, M. D., & Khoo, C. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.609110 · Cited by 87
Relationship Between Control of Glycemia and Gastric Emptying Disturbances in Diabetes Mellitus
Halland, M., & Bharucha, A. E. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.11.021 · Cited by 85
Probiotics for the treatment of type 2 diabetes: A review of randomized controlled trials
Tiderencel, K. A., Hutcheon, D. A., & Ziegler, J. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3213 · Cited by 82
Li, Z., Zhang, B., Wang, N., Zuo, Z., Hong Kui, W. E. I., & Zhao, F. (2022) · Gut · doi:10.1136/gutjnl-2022-328035 · Cited by 83
An overview of the pharmacokinetics, efficacy and safety of liraglutide
Bode, B. W. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.12.015 · Cited by 80
Gunnerud, U., Heinzle, C., Holst, J. J., Östman, E. M., & Björck, I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044731 · Cited by 79
Metabolic and cardiovascular benefits of GLP‑1 agonists, besides the hypoglycemic effect (Review)
Iorga, R., Bacalbașa, N., Carşote, M., Bratu, O. G., Stănescu, A. M. A., BUNGAU, S. G., Pantiș, C., & Diaconu, C. C. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8714 · Cited by 79
Long-term effects of weight-reducing drugs in people with hypertension
Siebenhofer, A., Winterholer, S., Jeitler, K., Horvath, K., Berghold, A., Krenn, C., & Semlitsch, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub5 · Cited by 70
Comprehensive Care Models for Cardiometabolic Disease
Reiter–Brennan, C., Dzaye, O. D. A., Davis, D. M., Blaha, M., & Eckel, R. H. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01450-1 · Cited by 76
Probiotics and nutraceuticals as a new frontier in obesity prevention and management
Kobyliak, N. M., Falalyeyeva, T. M., Boyko, N., Tsyryuk, O., Beregova, T. V., & Остапченко, Л. І. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.005 · Cited by 69
GLP-1 agonists: A review for emergency clinicians
Long, B., Pelletier, J., Koyfman, A., & Bridwell, R. E. (2024) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2024.01.010 · Cited by 67
Potential side effects to GLP-1 agonists: understanding their safety and tolerability
Consoli, A., & Formoso, G. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.987122 · Cited by 65
Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024) · Endocrinology · doi:10.1210/endocr/bqae155 · Cited by 61
Montoya, P. A., Múñoz, Ó., Cardozo, D. M. G., García, O. M., Fernandez-Ávila, D. G., Casas, L. Á., Bohórquez, L. F., Toro, C. M. A., Carvajal, L., de Peña, D. R., et al. (2016) · Colombia medica · doi:10.25100/cm.v47i2.2207 · Cited by 60
Bloomfield, H. E., Greer, N. L., Newman, D. R., MacDonald, R. H., Carlyle, M. H., FITZGERALD, P. J., Rutks, I. R., & Wilt, T. J. (2012) · Cited by 59
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
Crane, J. D., & McGowan, B. M. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315620180 · Cited by 67
Sun, F., Yu, K., Yang, Z., Wu, S., Zhang, Y., Shi, L., Ji, L., & Zhan, S. (2012) · Experimental Diabetes Research · doi:10.1155/2012/230624 · Cited by 58
Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes
Xu, J., & Rajaratnam, R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0499-5 · Cited by 58
Rivera, F. B., Lumbang, G. N. O., Gaid, D. R. M., Cruz, L. L. A., Magalong, J. V., Bantayan, N. R. B., Lara-Breitinger, K. M., Gulati, M., & Bakris, G. L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15529 · Cited by 59
Herzberg-Schäfer, S. A., Heni, M., Stefan, N., Häring, H., & Fritsche, A. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01648.x · Cited by 59
Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’
Skow, M., Bergmann, N. C., & Knop, F. K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12685 · Cited by 57
Perna, S., Mainardi, M., Astrone, P., Gozzer, C., Biava, A., Bacchio, R., Spadaccini, D., Solerte, S. B., & Rondanelli, M. (2018) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s164785 · Cited by 56
Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2017.12.003 · Cited by 57
Fiorentino, T. V., Casiraghi, F., Davalli, A. M., Finzi, G., Rosa, S. L., Higgins, P. B., ABRAHAMIAN, G. A., Marando, A., Sessa, F., Perego, C., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.93091 · Cited by 51
Clemente‐Suárez, V. J., Redondo-Flórez, L., Rubio-Zarapuz, A., Martín-Rodríguez, A., & Tornero-Aguilera, J. F. (2024) · Biomedicines · doi:10.3390/biomedicines12010221 · Cited by 59
Camilleri, M., Vázquez‐Roque, M. I., Iturrino, J., Boldingh, A., Burton, D. B., McKinzie, S., Wong, B. S., Rao, A. S., Kenny, E., Månsson, M., et al. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00076.2012 · Cited by 50
Zhao, Z., Tang, Y., Hu, Y., Zhu, H., Chen, X., & Zhao, B. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4162 · Cited by 49
Treatment of type 2 diabetes mellitus in elderly patients
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2017.12.004 · Cited by 48
Yanay, O., Bailey, A. L., Kernan, K. A., Zimmerman, J. J., & Osborne, W. R. A. (2015) · Journal of Inflammation Research · doi:10.2147/jir.s84993 · Cited by 46
An overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 49
Evans, M., McEwan, P. C., O'Shea, R., & George, L. (2012) · Diabetes Therapy · doi:10.1007/s13300-012-0015-6 · Cited by 43
Sauer, N., Rösch, T., Pezold, J., Reining, F., Anders, M., Groth, S., Schachschal, G., Mann, O., & Aberle, J. (2013) · Obesity Surgery · doi:10.1007/s11695-013-1005-0 · Cited by 43
Cai, H.-Y., Wang, Z., Hölscher, C., Li, Y., Zhang, J., Sun, P., Li, J., Yang, W., Wu, M., & Qi, J. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.10.033 · Cited by 46
Patoulias, D., Doumas, M. N., Kotsis, V., Stavropoulos, K., Imprialos, K. P., Zografou, I., Petidis, K., Bakatselos, S., & Karagiannis, A. I. (2020) · Current Diabetes Reviews · doi:10.2174/1573399815666190614141918 · Cited by 48
Bombesin receptor subtype 3 as a potential target for obesity and diabetes
González, N., Moreno, P., & Jensen, R. T. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1056154 · Cited by 42
Artificial Pancreas: Current Progress and Future Outlook in the Treatment of Type 1 Diabetes
Ramli, R., Reddy, M., & Oliver, N. S. (2019) · Drugs · doi:10.1007/s40265-019-01149-2 · Cited by 44
Kongmalai, T., Srinonprasert, V., Anothaisintawee, T., Kongmalai, P., McKay, G. J., Attia, J., & Thakkinstian, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1182037 · Cited by 43
Sun, F., Yu, K., Wu, S., Zhang, Y., Yang, Z., Shi, L., Ji, L., & Zhan, S. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.004 · Cited by 41
Pinelli, N. R., Berlie, H. D., & Hurren (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s27528 · Cited by 41
Liraglutide pretreatment attenuates sepsis-induced acute lung injury
Baer, B., Putz, N. D., Riedmann, K. J., Gonski, S. K., Lin, J., Ware, L. B., Toki, S., Peebles, R. S., Cahill, K. N., & Bastarache, J. A. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00041.2023 · Cited by 43
Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2017.12.003 · Cited by 42
Round, E., Engel, S. S., Golm, G. T., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0155-7 · Cited by 37
Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease
Fontes, A., Pagès, M. A. I., Oliveira, P. J., Ramalho‐Santos, J., Zischka, H., & Azul, A. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163987 · Cited by 38
Hosseinpour, A., Sood, A., Kamalpour, J., Zandi, E., Pakmehr, S., Hosseinpour, H., Sood, A., Agrawal, A., & Gupta, R. (2024) · Clinical Cardiology · doi:10.1002/clc.24314 · Cited by 40
Musazadeh, V., Anilou, M. M., Vajdi, M., Karimi, A., Ahrabi, S. S., & Dehghan, P. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1121541 · Cited by 36
Zang, L., Liu, Y., Geng, J., Luo, Y. M., Bian, F., Lv, X., Yang, J., Liu, J., Peng, Y., Li, Y., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12674 · Cited by 37
Incretin-based therapies and cardiovascular risk
Mannucci, E., & Dicembrini, I. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.678940 · Cited by 35
Ebdrup, B. H., Knop, F. K., Ishøy, P. L., Rostrup, E., Fagerlund, B., Lublin, H., & Glenthøj, B. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-92 · Cited by 34
Liraglutide for the treatment of type 2 diabetes
Shyangdan, D., Cummins, E., Royle, P., & Waugh, N. R. (2011) · Health Technology Assessment · doi:10.3310/hta15suppl1/09 · Cited by 35
Self-citationCimmaruta, D., Maiorino, M. I., Scavone, C., Sportiello, L., Rossi, F., Giugliano, D., Esposito, K., & Capuano, A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1221402 · Cited by 33
Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity.
Nolen-Doerr, E., Stockman, M.-C., & Rizo, I. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00350-4 · Cited by 32
Schmidt, L. J., Habacher, W., Augustin, T., Krahulec, E., & Semlitsch, T. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12269 · Cited by 31
Gao, F., Lv, X., Mo, Z., Ma, J., Zhang, Q., Yang, G., Liu, W., Li, Q., Zhou, J., Bao, Y., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14163 · Cited by 32
Bush, M., Scott, R., Watanalumlerd, P., Zhi, H., & Lewis, E. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.11.2613 · Cited by 30
Zhou, Y., Geng, Z., Wang, X., Huang, Y., Shen, L., & Wang, Y. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3223 · Cited by 30
The Antidiabetic Potential of Probiotics: A Review
Li, S., Liu, Z., Zhang, Q., Su, D., Wang, P., Li, Y., Shi, W., & Zhang, Q. (2024) · Nutrients · doi:10.3390/nu16152494 · Cited by 30
Combining a GLP-1 Receptor Agonist and Basal Insulin: Study Evidence and Practical Considerations
Carris, N. W., Taylor, J. R., & Gums, J. G. (2014) · Drugs · doi:10.1007/s40265-014-0325-2 · Cited by 28
van Baar, M. J. B., van der Aart, A. B., Hoogenberg, K., Joles, J. A., Heerspink, H. J. L., & van Raalte, D. H. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819865398 · Cited by 32
Mao, D., Cao, H., Shi, M., Wang, C. C., Kwong, J., Li, J. J. X., Hou, Y. J., Ming, X., Lee, H. M., Tian, X. Y., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103242 · Cited by 29
Gejl, M., Rungby, J., Brock, B., & GJEDDE, A. H. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12240 · Cited by 28
Vascular Complications of Diabetes Mellitus
Chiong, Y., & Evans‐Molina, C. (2014) · Springer eBooks · doi:10.1007/978-3-642-37078-6_49 · Cited by 28
Metadata
- Authors
- Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A.
- Affiliations
- University of Warwick (GB)
- Cochrane Metabolic and Endocrine Disorders Group; Researcher in Systematic Reviews; Hasenheide 67 Berlin Germany 10967
- University of Aberdeen (GB)
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2011-10-05
- Volume
- 2013
- Issue
- 7
- Pages
- CD006423-CD006423
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- PMC
- PMC6486297
- OpenAlex
- W1892323012
- Cited by
- 246
- References
- 100
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 23 · 2023: 13 · 2022: 4 · 2021: 13 · 2020: 14 · 2019: 15 · 2018: 15 · 2017: 14 · 2016: 22 · 2015: 25 · 2014: 22 · 2013: 17 · 2012: 29
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Warwick Research Archive Portal (University of Warwick) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, exenatide, liraglutide, glycemic control, insulin glargine, sitagliptin, pioglitazone, sulfonylureas, adverse effects, nausea, hypoglycemia
- MeSH terms
- Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Randomized Controlled Trials as Topic, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
